These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 23821040)

  • 1. Prospects for improving brain function in individuals with Down syndrome.
    Costa AC; Scott-McKean JJ
    CNS Drugs; 2013 Sep; 27(9):679-702. PubMed ID: 23821040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
    Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
    Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome.
    Costa AC
    Dev Neurosci; 2011; 33(5):414-27. PubMed ID: 21893967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
    De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
    Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.
    Parrini M; Ghezzi D; Deidda G; Medrihan L; Castroflorio E; Alberti M; Baldelli P; Cancedda L; Contestabile A
    Sci Rep; 2017 Dec; 7(1):16825. PubMed ID: 29203796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
    Wyganowska-Świątkowska M; Matthews-Kozanecka M; Matthews-Brzozowska T; Skrzypczak-Jankun E; Jankun J
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.
    Abeysekera I; Thomas J; Georgiadis TM; Berman AG; Hammond MA; Dria KJ; Wallace JM; Roper RJ
    Mol Nutr Food Res; 2016 Apr; 60(4):717-726. PubMed ID: 26748562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.
    Gardiner KJ
    Drug Des Devel Ther; 2015; 9():103-25. PubMed ID: 25552901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model.
    Valenti D; de Bari L; de Rasmo D; Signorile A; Henrion-Caude A; Contestabile A; Vacca RA
    Biochim Biophys Acta; 2016 Jun; 1862(6):1093-104. PubMed ID: 26964795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.
    Braudeau J; Delatour B; Duchon A; Pereira PL; Dauphinot L; de Chaumont F; Olivo-Marin JC; Dodd RH; Hérault Y; Potier MC
    J Psychopharmacol; 2011 Aug; 25(8):1030-42. PubMed ID: 21693554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.
    Lockrow J; Boger H; Bimonte-Nelson H; Granholm AC
    Behav Brain Res; 2011 Aug; 221(2):610-22. PubMed ID: 20363261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.
    Boada R; Hutaff-Lee C; Schrader A; Weitzenkamp D; Benke TA; Goldson EJ; Costa AC
    Transl Psychiatry; 2012 Jul; 2(7):e141. PubMed ID: 22806212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test.
    Costa AC; Scott-McKean JJ; Stasko MR
    Neuropsychopharmacology; 2008 Jun; 33(7):1624-32. PubMed ID: 17700645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
    Nguyen TL; Duchon A; Manousopoulou A; Loaëc N; Villiers B; Pani G; Karatas M; Mechling AE; Harsan LA; Limanton E; Bazureau JP; Carreaux F; Garbis SD; Meijer L; Herault Y
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30115750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress and Down syndrome. Do antioxidants play a role in therapy?
    Muchová J; Žitňanová I; Ďuračková Z
    Physiol Res; 2014; 63(5):535-42. PubMed ID: 24908086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS.
    Stagni F; Giacomini A; Guidi S; Emili M; Uguagliati B; Salvalai ME; Bortolotto V; Grilli M; Rimondini R; Bartesaghi R
    Exp Neurol; 2017 Dec; 298(Pt A):79-96. PubMed ID: 28882412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
    Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Memory and Cognition in Individuals with Down Syndrome.
    Rafii MS
    CNS Drugs; 2016 Jul; 30(7):567-73. PubMed ID: 27272473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down syndrome--recent progress and future prospects.
    Wiseman FK; Alford KA; Tybulewicz VL; Fisher EM
    Hum Mol Genet; 2009 Apr; 18(R1):R75-83. PubMed ID: 19297404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.